Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Asayama

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Japanese Journal of Infectious Diseases|August 25, 2000
Acute hepatitis outbreak in Tokyo caused by hepatitis A virus of common origin transmitted through oral and sexual routesM Baba, H Oka, M Asayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patientsK Shitara, T Yamanaka, T Denda, et al.
ESMO Open|March 21, 2021
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7T Takahashi, K Yamazaki, E Oki, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancerT Sakakida, T Masuishi, M Asayama, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Japanese Journal of Infectious Diseases|August 25, 2000
Acute hepatitis outbreak in Tokyo caused by hepatitis A virus of common origin transmitted through oral and sexual routesM Baba, H Oka, M Asayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patientsK Shitara, T Yamanaka, T Denda, et al.
ESMO Open|March 21, 2021
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7T Takahashi, K Yamazaki, E Oki, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancerT Sakakida, T Masuishi, M Asayama, et al.
Pageof 4